They won !!!!!
Scrip @PharmaScrip 51s52 seconds ago
.@Summitplc’s Phase II CoDIFy study win #ScripAwards 2016 QuintilesIMS' Clinical Advance of the Year Award
0 replies 0 retweets 0 likes
Reply Retweet
Like
More
Yesterdays tweet by Summit at least they are moving forward:
Summit Therapeutics @Summitplc 18h18 hours ago
We're hiring! Details: http://www.summitplc.com/about/careers/ Join our team to help fight #Duchenne and #Cdiff
Per someuwin from the other board this afternoon:
Sarepta Therapeutics (NASDAQ:SRPT) initiated with Outperform rating and $68 (39% upside) price target by Credit Suisse.
Per waterloo01 from other board this morning:
http://www.dailystockplays.com/Bullish-Cross-2016-10-13.html
Stocks with Bullish 50/200-day MA Crossovers signal an emerging uptrend. Here are the Bullish 50/200-day MA Crossovers on 10-13-2016 for trading on 10-14-2016
HEAR, SALT, NQ, SMMT
Summit Therapeutics Retweeted this evening.
MuscularDystrophyUK @MDUK_News 1h1 hour ago
Join us Wednesday 6-7pm to put your Qs on #utrophin to Prof Dame Kay Davies & Richard Pye from @Summitplc #Duchenne hxxp://qoo.ly/bcxji
https://twitter.com/summitplc
Looking at todays results I wish I had bought in here. I agree with the previous poster and was once an investor but sold at 935 down on where I should have been. Those wishing to take the risk this share looks like a good Buy for those with funds.
Hi Robster63 - I agree with you and there have been a number of other places that are suggesting it as a share to buy.They are 'cheap as chips' and in my opinion a good buy. GLA